SMC LTD.
SMC Ltd. provides world-class device contract manufacturing with complete services for the Drug Delivery, Diagnostics, and Medical Device markets. Concept through commercialization services include: design, device development, manufacturing of clinical trials, and commercial scalable manufacturing. Services also include integration of filled primary drug containers with secondary packaging and distribution. Our global facilities are ISO 13485 certified, FDA registered, cGMP and Part 4 compliant.
Oval Medical Technologies, an SMC Ltd. Company, provides robust autoinjector platforms to meet the needs of patients and a broad range of drugs including biologics. Oval’s patented integrated primary drug container technology provides customers with complete service from customization of subcutaneous and intramuscular platforms, to production of clinical trials devices and commercial scale manufacturing.
FEATURED CONTENT
-
A New Mindset For Combination Product Development
As we balance the time-to-market and risk for novel therapies, we must anticipate changing needs for combination device development, highlighting the technological paradigm shift.
-
Sustainability Considerations For Drug Delivery Device End-To-End Solutions
Learn how to address the gradual unlinking of economic activity from the consumption of finite resources and the removal of waste to support and help prevent a global climate catastrophe.
-
Accelerating Novel Therapies To The Market
The formulations for novel therapeutics require flexibility to support adaptive sterile manufacturing and an integrated approach for a path from development, to small batch manufacturing, to commercialization.
-
Computational Modeling Of Injection-Related Tissue Responses
Optimizing delivery along with the formulation is the key to successful clinical outcomes. Research is necessary to understand the relationship between body morphology, injection force, and needle length.
-
High Viscosity Formulations: Developing A 'Human Solution' To Autoinjector Design
Delivering high viscosity (HV) formulations with a truly human solution involves a balance between safety and practicality. Learn the importance of achieving this solution with HV autoinjector design.
-
Characterization & Delivery Of Ultra-Viscous & Non-Newtonian Formulations
Discover how to identify characteristics at the earliest stage, a vital step in autoinjector device platform development, with the use of the innovative Injection Characterization System (ICS).
-
Patient-Centricity: The Importance Of Human Factors In The Pandemic Era
Discover how patient-centricity is at the heart of drug delivery device design and innovation and how the global pandemic has highlighted the importance of patient-centric development in this field.
-
Integrating Design And Industrialization To Optimize Cost, Quality & Time
Explore how integrating design and industrialization teams can optimize the cost, quality, and time of developing a novel drug delivery system.
-
Meeting The Challenge Of Delivering High-Volume Biologic Therapies
As the industry moves toward self-administration to reduce healthcare costs and improve patient convenience, there is a compelling need for simple-to-use, low-cost, disposable devices.
-
High Viscosity Formulations: Developing An Effective Primary Drug Container System
The past few years have seen a significant increase in the number of high viscosity (HV) formulations (100 – 1000 cP) being developed. There are a number of steps that autoinjector developers can take to meet the challenges posed by such formulations. This white paper focuses on some of the techniques used to develop the ArQ™-Bios high viscosity platform.
-
Choosing A CMO: Find The Best Match By Asking The Right Questions
When selecting a CMO, it’s important to look at organizational alignment, senior leadership engagement, program management, commitment to projects large and small, and processes in place to manage risk.
-
Insights Into Drug Delivery Device Manufacturing From Development Through Commercialization
Biologics and other targeted therapy techniques are creating opportunities for innovative device solutions that meet the needs of specific patient groups. As these therapies often require low annual volumes, the associated device manufacturing strategy must also fit commercial expectations, even at those volumes.
-
Keys To Driving Consistent Quality In Contract Manufacturing
Complex products and supply chains present plenty of opportunities for failure, especially when new products are being developed and launched. This article discusses key ingredients to robust and advanced quality planning that are essential to quality in contract manufacturing.
-
How To Design Autoinjectors For Highly Viscous Formulations
The design of autoinjectors for increasingly viscous, high-volume drug requirements presents challenges in today’s pharma market. New materials offer opportunities to overcome these challenges.
-
'Smart Devices' vs. 'Smart Design' In User-Centric Autoinjector Design
Oval Medical has developed a novel Prefilled Primary Drug Container that resolves many drug compatibility and functionality issues associated with the use of traditional glass syringe and rubber plunger technologies.
-
Improved Autoinjector Design Integrates Cyclic Olefin Syringe
Oval Medical has developed a novel Prefilled Primary Drug Container that resolves many compatibility and functionality issues associated with traditional glass syringe and rubber plunger technologies.
-
Drug Characterization: Key To Autoinjector Design For Challenging Formulations
This article discusses the process used for the delivery of challenging formulations through understanding their properties and the challenges they pose at the very earliest stage in the design process.
-
Using Polymeric PDC Technology To Improve Auto-Injector Design
The limitations of using glass-based auto-injectors, such as contamination, and the need for delivering complex, viscous preparations, have led to a new approach that uses polymeric PDC technology instead. This article takes a look at what polymeric PDCs can offer in making auto-injectors truly patient-centric.
-
Combining Human Needs With High Viscosity Formulations
Explore the requirements of designing an autoinjector capable of handling the high pressures necessary for the delivery of highly viscous drug formulations with minimal impact on the patient.
CONTACT INFORMATION
SMC Ltd.
330 SMC Drive
Somerset, WI 54025
UNITED STATES
Phone: 715.247.3500
Contact: inquiry@smcltd.com
FEATURED DRUG DELIVERY PRODUCTS
OUTSOURCED SERVICES
FEATURED ARTICLES
- How DFM Promotes Scalability, Repeatability, And Profitability
- Partnership Goals For Scale-Up Success
- Embrace A Contract Manufacturer Partnership That Drives Sustainability
- Applying Automation To The Manufacture Of Drug Delivery Devices
- Optimizing CMO Partnerships
- CM Partnering For Adaptable, Accelerated Market Acceptance
- A New Mindset For Combination Product Development
- Accelerating Novel Therapies To The Market
- Computational Modeling Of Injection-Related Tissue Responses
- Sustainability Considerations For Drug Delivery Device End-To-End Solutions
- High Viscosity Formulations: Developing A 'Human Solution' To Autoinjector Design
- Characterization & Delivery Of Ultra-Viscous & Non-Newtonian Formulations
- Patient-Centricity: The Importance Of Human Factors In The Pandemic Era
- Integrating Design And Industrialization To Optimize Cost, Quality & Time
- Meeting The Challenge Of Delivering High-Volume Biologic Therapies
- High Viscosity Formulations: Developing An Effective Primary Drug Container System
- Finding The Ideal Balance — Where Risk And Cost Of Quality Meet
- How To Design Autoinjectors For Highly Viscous Formulations
- 'Smart Devices' vs. 'Smart Design' In User-Centric Autoinjector Design
- Improved Autoinjector Design Integrates Cyclic Olefin Syringe
FEATURED NEWS
- SMC Pharma Services Enters Autoinjector Development Agreement With A Biopharmaceutical Company For The Bios Platform
- SMC Ltd. Announces Major Expansion Of Devens' Massachusetts Facility
- SMC Ltd. Announces Expansion Of Sterile Fill Finish Capabilities, Unveiling State-Of-The-Art Facility In North Carolina
- Uri Baruch Named As New Vice President And General Manager Of SMC Ltd.'s UK Division
- Cambridge Pharma Opens On The Cambridge Research Park